To study the Effectiveness of Oral Nutrition Supplement in Obese Population.â??

Not Applicable

Completed

• Registration Number: CTRI/2021/09/036636
• Lead Sponsor: Signutra Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-01-20
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 107

Inclusion Criteria

oSubjects with abdominal obesity: Waist circumference >= 102 cm and >= 88 cm, in men and women, respectively and BMI >=30.0 kg/m2

Exclusion Criteria

oSubjects not capable of understanding the informed consent.

oSubjects who are on lipid lowering treatment with statins, fibrates, etc. with a known dose change over the latest 3 months (changes not allowed during the trial)

oPresence of metabolic chronic disease, including type 2 diabetes (HbA1c >6.5) or hypothyroidism.

oObesity secondary to other underlying diseases such as Cushingâ??s syndrome, hypothyroidism, etc.

oTreatment with corticosteroids as well as other drugs known to significantly influence body weight, such as GLP-1 agonists.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- To determine efficacy of Vidaslim® in weight loss among obese population. <br/ ><br>- To determine safety and compliance of Vidaslim® in weight loss among obese population.Timepoint: 0 8 16 weeks

Secondary Outcome Measures

Name	Time	Method
- To determine safety and compliance of Vidaslim® in weight loss among obese population.Timepoint: 0 8 16 weeks